You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxaprozin
Accession NumberDB00991  (APRD00030)
TypeSmall Molecule
GroupsApproved
DescriptionOxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis.
Structure
Thumb
Synonyms
Danoprox
Daypro
Dayrun
Deflam
Duraprox
Oxaprozina
Oxaprozine
Oxaprozinum
Walix
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dayprotablet, film coated600 mg/1oralG.D. Searle LLC Division of Pfizer Inc1992-10-29Not applicableUs
Dayprotablet, film coated600 mg/1oralPd Rx Pharmaceuticals, Inc.1992-10-29Not applicableUs
Dayprotablet600 mgoralPfizer Canada Inc1997-01-072012-09-20Canada
Oxaprozintablet, film coated600 mg/1oralGreenstone LLC2013-03-28Not applicableUs
Rhoxal-oxaprozintablet600 mgoralRhoxalpharma Inc2001-06-112009-11-24Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-oxaprozintablet600 mgoralApotex Inc2001-05-29Not applicableCanada
Oxaprozintablet, film coated600 mg/1oralH.J. Harkins Company, Inc.2001-01-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralTeva Pharmaceuticals USA Inc2003-05-12Not applicableUs
Oxaprozintablet, film coated600 mg/1oralbryant ranch prepack2010-09-08Not applicableUs
Oxaprozintablet600 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2002-01-03Not applicableUs
Oxaprozintablet, film coated600 mg/1oralPreferred Pharmaceuticals, Inc2012-02-14Not applicableUs
Oxaprozintablet600 mg/1oralAv Kare, Inc.2014-03-06Not applicableUs
Oxaprozintablet600 mg/1oralPhysicians Total Care, Inc.2001-09-04Not applicableUs
Oxaprozintablet600 mg/1oralEon Labs, Inc.2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralDispensing Solutions, Inc.2001-01-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralClinical Solutions Wholesale2001-01-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-05-26Not applicableUs
Oxaprozintablet, film coated600 mg/1oralDr. Reddy's Laboratories Limited2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralSTAT Rx USA LLC2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Oxaprozintablet, film coated600 mg/1oralApotex Corp.2004-09-03Not applicableUs
Oxaprozintablet, film coated600 mg/1oralUnit Dose Services2010-09-08Not applicableUs
Oxaprozintablet, film coated600 mg/1oralPd Rx Pharmaceuticals, Inc.2010-09-08Not applicableUs
Oxaprozintablet, film coated600 mg/1oralRebel Distributors Corp2010-09-08Not applicableUs
Oxaprozintablet600 mg/1oralCarilion Materials Management2001-01-31Not applicableUs
Oxaprozintablet600 mg/1oralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlvoNot Available
Daypro AltaNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Oxaprozin potassium
ThumbNot applicableDBSALT001452
Categories
UNIIMHJ80W9LRB
CAS number21256-18-8
WeightAverage: 293.3166
Monoisotopic: 293.105193351
Chemical FormulaC18H15NO3
InChI KeyInChIKey=OFPXSFXSNFPTHF-UHFFFAOYSA-N
InChI
InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
IUPAC Name
3-(diphenyl-1,3-oxazol-2-yl)propanoic acid
SMILES
OC(=O)CCC1=NC(=C(O1)C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2,4,5-trisubstituted oxazoles. These are compounds containing an oxazole ring substituted at positions 2, 4 and 5 only. Oxazole is a five-membered aromatic heterocycle with one oxygen, one nitrogen, and three carbon atoms. Isomers include 1,2-oxazole and 1,3-oxazole.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassOxazoles
Direct Parent2,4,5-trisubstituted oxazoles
Alternative Parents
Substituents
  • 2,4,5-trisubstituted 1,3-oxazole
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed to relieve the inflammation, swelling, stiffness, and joint pain associated with rheumatoid arthritis and osteoarthritis.
PharmacodynamicsOxaprozin is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Oxaprozin is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and to alleviate moderate pain.
Mechanism of actionAnti-inflammatory effects of Oxaprozin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Oxaprozin is a non-selective NSAID, with a cell assay system showing lower COX-2 selectivity implying higher COX-1 selectivity.
Related Articles
AbsorptionOxaprozin is 95% absorbed after oral administration. Food may reduce the rate of absorption of oxaprozin, but the extent of absorption is unchanged. Antacids do not significantly affect the extent and rate of oxaprozin absorption.
Volume of distribution
  • 11 to 17 L/70 kg
Protein binding>99.5% bound to albumin
Metabolism

Hepatic. Ester and ether glucuronide are the major conjugated metabolites of oxaprozin, and do not have significant pharmacologic activity.

Route of eliminationOxaprozin is expected to be excreted in human milk based on its physical-chemical properties; however, the amount of oxaprozin excreted in breast milk has not been evaluated. Approximately 95% of oxaprozin is metabolized by the liver. Approximately 5% of the oxaprozin dose is excreted unchanged in the urine. Sixty-five percent (65%) of the dose is excreted in the urine and 35% in the feces as metabolite. Biliary excretion of unchanged oxaprozin is a minor pathway. Several oxaprozin metabolites have been identified in human urine or feces.
Half life54.9 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 1210 mg/kg; Oral, rabbit: LD50 = 172 mg/kg; Oral, rat: LD50 = 4470 mg/kg
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Oxaprozin Action PathwayDrug actionSMP00113
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9512
Caco-2 permeable-0.5255
P-glycoprotein substrateNon-substrate0.7938
P-glycoprotein inhibitor INon-inhibitor0.8801
P-glycoprotein inhibitor IINon-inhibitor0.9047
Renal organic cation transporterNon-inhibitor0.8467
CYP450 2C9 substrateNon-substrate0.7623
CYP450 2D6 substrateNon-substrate0.8163
CYP450 3A4 substrateNon-substrate0.5781
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9327
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.93
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6313
Ames testNon AMES toxic0.9191
CarcinogenicityNon-carcinogens0.9364
BiodegradationReady biodegradable0.6095
Rat acute toxicity1.8484 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9906
hERG inhibition (predictor II)Non-inhibitor0.9123
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Gd searle llc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Caraco pharmaceutical laboratories ltd
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories
Packagers
Dosage forms
FormRouteStrength
Tabletoral600 mg
Tablet, film coatedoral600 mg/1
Tabletoral600 mg/1
Prices
Unit descriptionCostUnit
Daypro 600 mg tablet2.98USD tablet
Daypro 600 mg caplet2.87USD caplet
Oxaprozin 600 mg tablet1.54USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6030643 No1997-05-162017-05-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point158-159 °CNot Available
water solubilityInsolubleNot Available
logP4.19HANSCH,C ET AL. (1995)
pKa4.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0325 mg/mLALOGPS
logP3.33ALOGPS
logP3.46ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.95ChemAxon
pKa (Strongest Basic)-0.59ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.33 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.88 m3·mol-1ChemAxon
Polarizability31.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference
  1. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. Pubmed
General References
  1. Heller B, Tarricone R: Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin. 2004 Aug;20(8):1279-90. [PubMed:15324531 ]
External Links
ATC CodesM01AE12
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (47 KB)
MSDSDownload (63.1 KB)
Interactions
Drug Interactions
Drug
AbciximabOxaprozin may increase the anticoagulant activities of Abciximab.
AbirateroneThe metabolism of Oxaprozin can be decreased when combined with Abiraterone.
AcebutololOxaprozin may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Aceclofenac.
AcenocoumarolOxaprozin may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Oxaprozin.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Oxaprozin.
Alendronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.
AliskirenOxaprozin may decrease the antihypertensive activities of Aliskiren.
AlprenololOxaprozin may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxaprozin.
AmikacinOxaprozin may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideOxaprozin may decrease the antihypertensive activities of Amiloride.
AmiodaroneThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.
AncrodOxaprozin may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.
Antithrombin III humanOxaprozin may increase the anticoagulant activities of Antithrombin III human.
ApixabanOxaprozin may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Apremilast.
AprepitantThe metabolism of Oxaprozin can be increased when combined with Aprepitant.
ArdeparinOxaprozin may increase the anticoagulant activities of Ardeparin.
ArgatrobanOxaprozin may increase the anticoagulant activities of Argatroban.
ArotinololOxaprozin may decrease the antihypertensive activities of Arotinolol.
AtenololOxaprozin may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.
BalsalazideOxaprozin may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Oxaprozin.
BecaplerminOxaprozin may increase the anticoagulant activities of Becaplermin.
BefunololOxaprozin may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxaprozin.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.
BenoxaprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Benoxaprofen.
BetaxololOxaprozin may decrease the antihypertensive activities of Betaxolol.
BevantololOxaprozin may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxaprozin.
BisoprololOxaprozin may decrease the antihypertensive activities of Bisoprolol.
BivalirudinOxaprozin may increase the anticoagulant activities of Bivalirudin.
BopindololOxaprozin may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.
BufuralolOxaprozin may decrease the antihypertensive activities of Bufuralol.
BumetanideOxaprozin may decrease the diuretic activities of Bumetanide.
BupranololOxaprozin may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Oxaprozin.
CapecitabineThe metabolism of Oxaprozin can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Oxaprozin.
CarbamazepineThe metabolism of Oxaprozin can be increased when combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxaprozin.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Oxaprozin.
CarteololOxaprozin may decrease the antihypertensive activities of Carteolol.
CarvedilolOxaprozin may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oxaprozin.
CeliprololOxaprozin may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Oxaprozin can be increased when it is combined with Ceritinib.
CertoparinOxaprozin may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Oxaprozin.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxaprozin.
CholecalciferolThe metabolism of Oxaprozin can be decreased when combined with Cholecalciferol.
CholestyramineCholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxaprozin.
Citric AcidOxaprozin may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Oxaprozin.
ClotrimazoleThe metabolism of Oxaprozin can be decreased when combined with Clotrimazole.
ColesevelamColesevelam can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineOxaprozin may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Oxaprozin can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with D-Limonene.
Dabigatran etexilateOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Oxaprozin can be decreased when it is combined with Dabrafenib.
DalteparinOxaprozin may increase the anticoagulant activities of Dalteparin.
DanaparoidOxaprozin may increase the anticoagulant activities of Danaparoid.
DaunorubicinOxaprozin may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.
DelavirdineThe metabolism of Oxaprozin can be decreased when combined with Delavirdine.
DesirudinOxaprozin may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxaprozin.
DextranOxaprozin may increase the anticoagulant activities of Dextran.
Dextran 40Oxaprozin may increase the anticoagulant activities of Dextran 40.
Dextran 70Oxaprozin may increase the anticoagulant activities of Dextran 70.
Dextran 75Oxaprozin may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Oxaprozin.
DicoumarolOxaprozin may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Oxaprozin.
DihydrostreptomycinOxaprozin may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxaprozin.
DoxorubicinOxaprozin may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneOxaprozin may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Droxicam.
Edetic AcidOxaprozin may increase the anticoagulant activities of Edetic Acid.
EdoxabanOxaprozin may increase the anticoagulant activities of Edoxaban.
EfavirenzThe metabolism of Oxaprozin can be decreased when combined with Efavirenz.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxaprozin.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Oxaprozin.
EnoxaparinOxaprozin may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Epirizole.
EpirubicinOxaprozin may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneOxaprozin may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.
EsmololOxaprozin may decrease the antihypertensive activities of Esmolol.
Etacrynic acidOxaprozin may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.
Ethyl biscoumacetateOxaprozin may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Oxaprozin.
EtofenamateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.
EtravirineThe metabolism of Oxaprozin can be decreased when combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Oxaprozin is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxaprozin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Oxaprozin.
FloxuridineThe metabolism of Oxaprozin can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Oxaprozin can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunixin.
FluorouracilThe metabolism of Oxaprozin can be decreased when combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxaprozin.
FluvastatinThe metabolism of Oxaprozin can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Oxaprozin can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxaprozin.
Fondaparinux sodiumOxaprozin may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Oxaprozin.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Oxaprozin.
FosphenytoinThe metabolism of Oxaprozin can be increased when combined with Fosphenytoin.
FramycetinOxaprozin may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideOxaprozin may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxaprozin.
GemfibrozilThe metabolism of Oxaprozin can be decreased when combined with Gemfibrozil.
GentamicinOxaprozin may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
HeparinOxaprozin may increase the anticoagulant activities of Heparin.
HirulogOxaprozin may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Oxaprozin is combined with HMPL-004.
HydralazineOxaprozin may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxaprozin.
Hygromycin BOxaprozin may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Icatibant.
IdarubicinOxaprozin may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.
IndenololOxaprozin may decrease the antihypertensive activities of Indenolol.
IndinavirThe metabolism of Oxaprozin can be decreased when combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.
IndoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Oxaprozin.
IsoxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Isoxicam.
KanamycinOxaprozin may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Kebuzone.
KetoconazoleThe metabolism of Oxaprozin can be decreased when combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.
LabetalolOxaprozin may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Leflunomide.
LepirudinOxaprozin may increase the anticoagulant activities of Lepirudin.
LevobunololOxaprozin may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Oxaprozin.
LithiumThe serum concentration of Lithium can be increased when it is combined with Oxaprozin.
LornoxicamThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Oxaprozin.
LovastatinThe metabolism of Oxaprozin can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxaprozin.
LumacaftorThe serum concentration of Oxaprozin can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Oxaprozin.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxaprozin.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.
MesalazineOxaprozin may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Oxaprozin.
MetamizoleThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.
MetipranololOxaprozin may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.
MetoprololOxaprozin may decrease the antihypertensive activities of Metoprolol.
MetrizamideOxaprozin may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MifepristoneThe serum concentration of Oxaprozin can be increased when it is combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxaprozin.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Oxaprozin.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Oxaprozin.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Oxaprozin.
NadololOxaprozin may decrease the antihypertensive activities of Nadolol.
NadroparinOxaprozin may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Oxaprozin.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Oxaprozin.
NCX 4016The risk or severity of adverse effects can be increased when Oxaprozin is combined with NCX 4016.
NeomycinOxaprozin may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nepafenac.
NetilmicinOxaprozin may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe metabolism of Oxaprozin can be decreased when combined with Nicardipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Oxaprozin.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.
OlsalazineOxaprozin may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oxaprozin.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Oxaprozin.
OmeprazoleThe metabolism of Oxaprozin can be decreased when combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Orgotein.
OtamixabanOxaprozin may increase the anticoagulant activities of Otamixaban.
OxprenololOxaprozin may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Parecoxib.
ParomomycinOxaprozin may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololOxaprozin may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateOxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxaprozin.
PhenindioneOxaprozin may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe metabolism of Oxaprozin can be increased when combined with Phenobarbital.
PhenprocoumonOxaprozin may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxaprozin.
PhenytoinThe metabolism of Oxaprozin can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.
PindololOxaprozin may decrease the antihypertensive activities of Pindolol.
PiretanideOxaprozin may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.
PlicamycinOxaprozin may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxaprozin.
PractololOxaprozin may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Oxaprozin.
PrimidoneThe metabolism of Oxaprozin can be increased when combined with Primidone.
ProbenecidThe serum concentration of Oxaprozin can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Propacetamol.
PropranololOxaprozin may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Oxaprozin.
Protein COxaprozin may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeOxaprozin may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Oxaprozin is combined with PTC299.
PuromycinOxaprozin may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
PyrimethamineThe metabolism of Oxaprozin can be decreased when combined with Pyrimethamine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Oxaprozin.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxaprozin.
QuinineThe metabolism of Oxaprozin can be decreased when combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Oxaprozin.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Oxaprozin.
ResveratrolThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.
ReviparinOxaprozin may increase the anticoagulant activities of Reviparin.
RibostamycinOxaprozin may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe metabolism of Oxaprozin can be increased when combined with Rifampicin.
RifapentineThe metabolism of Oxaprozin can be increased when combined with Rifapentine.
RisedronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.
RivaroxabanOxaprozin may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Oxaprozin.
SalicylamideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxaprozin.
SalsalateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Oxaprozin.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Oxaprozin.
SecobarbitalThe metabolism of Oxaprozin can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Seratrodast.
SildenafilThe metabolism of Oxaprozin can be decreased when combined with Sildenafil.
SorafenibThe metabolism of Oxaprozin can be decreased when combined with Sorafenib.
SotalolOxaprozin may decrease the antihypertensive activities of Sotalol.
SpectinomycinOxaprozin may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Oxaprozin.
SpironolactoneOxaprozin may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Oxaprozin is combined with SRT501.
StreptomycinOxaprozin may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinOxaprozin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfadiazineThe metabolism of Oxaprozin can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Oxaprozin can be decreased when combined with Sulfamethoxazole.
SulfasalazineOxaprozin may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxaprozin.
SulfisoxazoleThe metabolism of Oxaprozin can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Oxaprozin.
SulodexideOxaprozin may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.
TacrolimusOxaprozin may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Oxaprozin.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Oxaprozin.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Oxaprozin.
TenofovirThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxaprozin.
TepoxalinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.
TicagrelorThe metabolism of Oxaprozin can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Oxaprozin can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiludronate.
TimololOxaprozin may decrease the antihypertensive activities of Timolol.
TobramycinOxaprozin may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TolbutamideThe metabolism of Oxaprozin can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.
TorasemideOxaprozin may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Oxaprozin.
TranilastThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.
TriamtereneOxaprozin may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.
TrimethoprimThe metabolism of Oxaprozin can be decreased when combined with Trimethoprim.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Oxaprozin.
Valproic AcidThe metabolism of Oxaprozin can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Oxaprozin.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Oxaprozin.
VoriconazoleThe metabolism of Oxaprozin can be decreased when combined with Voriconazole.
WarfarinOxaprozin may increase the anticoagulant activities of Warfarin.
XimelagatranOxaprozin may increase the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Oxaprozin can be decreased when combined with Zafirlukast.
ZaltoprofenThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Oxaprozin.
Zoledronic acidThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Zomepirac.
Food Interactions
  • Take with food, usually once a day after breakfast. Food decreases the rate of absorption but not the amount absorbed. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331 ]
  2. Kean WF: Oxaprozin: kinetic and dynamic profile in the treatment of pain. Curr Med Res Opin. 2004 Aug;20(8):1275-7. [PubMed:15324530 ]
  3. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416 ]
  4. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579 ]
  5. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Yood MU, Watkins E, Wells K, Kucera G, Johnson CC: The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. Pharmacoepidemiol Drug Saf. 2006 Dec;15(12):852-60. [PubMed:17024689 ]
  2. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T, Mizushima Y: Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998 Apr 17;347(1):87-94. [PubMed:9650852 ]
  3. Kawai S: Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration. Inflamm Res. 1998 Oct;47 Suppl 2:S102-6. [PubMed:9831331 ]
  4. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S: Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25. [PubMed:12065695 ]
  5. Zhou XP, Zhang MX, Sun W, Yang XH, Wang GS, Sui DY, Yu XF, Qu SC: Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug. Biol Pharm Bull. 2009 Dec;32(12):1986-90. [PubMed:19952416 ]
  6. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F: Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157(2):294-306. doi: 10.1111/j.1476-5381.2009.00162.x. Epub 2009 Mar 26. [PubMed:19338579 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23